Abrinica, Clyde .
HRN: 27-22-75 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/16/2025
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
10/16/2025
10/23/2025
IV
400mg
Q 6 Hours
HAP (VAP)
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes